Group items matching

in title, tags, annotations or url

i. Purpose: The purpose of these activities is to support the goals of the HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, 2014-2016 (available at http://aids.gov/pdf/viral-hepatitis-action-plan.pdf) by ensuring Hepatitis B-infected pregnant women are identified so that their infants can receive timely post-exposure prophylaxis, improvements in post-vaccination serologic testing to improve efficiencies, and data collection to assess infant outcomes ii. Outcomes: Increased identification of Hepatitis B-infected pregnant women; increased rates of post-vaccination serologic testing among infants born to Hepatitis B-infected pregnant women; and assessment of factors associated with infant outcomes iii. Strategies and Activities: Collaborations: To maximize opportunities for Hepatitis B prevention through vaccination, referral for care, and treatment of persons found to have chronic Hepatitis B infection, this FOA encourages Perinatal Hepatitis B Prevention Program collaborations and service integration as a program imperative of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Such collaborations can increase efficiency, reduce redundancy, eliminate missed opportunities, and improve outcomes through the use of shared data and services. a. With CDC-funded programs: Applicants should create and build upon internal health department collaborations to improve identification of Hepatitis B-infected pregnant women; screen their household and sexual contacts for Hepatitis B and complete vaccination of susceptible persons; refer persons with chronic Hepatitis B infection for care and treatment; and report infants, household, and sexual contacts with chronic Hepatitis B infection to the National Notifiable Diseases Surveillance System. b. With organizations external to CDC: Opportunities for collaboration with non-CDC organizations will be encouraged; non-CDC organizations may include commercial laboratories and health system

This Funding Opportunity Announcement (FOA) invites applications to develop short-term tests that provide a comprehensive measure of resilience in animal models used in aging studies. Resilience is defined here as the ability of an organism to respond to physical challenges or stresses and return to homeostasis. Increased resilience is believed to correlate with longevity and a longer health-span, but appropriate methodology to test this comprehensibly in animal models is currently lacking. The purpose of this FOA is to develop appropriate tests to measure resilience to physical, molecular and cellular stresses, as a prelude to being able to predict, using a panel of standardized short-term tests in young or middle-aged animals, whether interventions might lead to improved future health outcomes and longevity.

This Funding Opportunity Announcement (FOA) invites applications to develop short-term tests that provide a comprehensive measure of resilience in animal models used in aging studies. Resilience is defined here as the ability of an organism to respond to physical challenges or stresses and return to homeostasis. Increased resilience is believed to correlate with longevity and a longer health-span, but appropriate methodology to test this comprehensibly in animal models is currently lacking. The purpose of this FOA is to develop appropriate tests to measure resilience to physical, molecular and cellular stresses, as a prelude to being able to predict, using a panel of standardized short-term tests in young or middle-aged animals, whether interventions might lead to improved future health outcomes and longevity.

This FOA invites applications for the Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing Program to develop highly reproducible and translatable in vitro models for preclinical efficacy studies through discovery and validation of translatable biomarkers, development of standardized methods for preclinical efficacy Testing and definitive efficacy Testing of candidate therapeutics using best practices and rigorous study design. An essential feature will be a multidisciplinary approach that brings together experts in bioengineering, microfluidics, material science, "omic" sciences, computational biology, disease biology, pathology, electrophysiology, pharmacology, biostatistics and clinical science.

This FOA invites applications for the Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing Program to develop highly reproducible and translatable in vitro models for preclinical efficacy studies through discovery and validation of translatable biomarkers, development of standardized methods for preclinical efficacy Testing and definitive efficacy Testing of candidate therapeutics using best practices and rigorous study design. An essential feature will be a multidisciplinary approach that brings together experts in bioengineering, microfluidics, material science, "omic" sciences, computational biology, disease biology, pathology, electrophysiology, pharmacology, biostatistics and clinical science.

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

The Aging Interventions Testing Program (ITP) tests, under standardized conditions, potential intervention strategies which may decelerate the rate of aging in mammals. The rate of aging is to be measured by lifespan extension and/or improvements in health at later ages due to the intervention. The ITP has used lifespan as its primary outcome for an intervention, with limited studies on end-of-life pathologies and selected tests of health across the lifespan (health span). This FOA calls for renewal of the ITP with the following goals: 1) Continue to test compounds for effects on lifespan; 2) Increase histology and pathophysiology analyses at time of death; 3) Increase focused studies of health span on selected compounds.

The purpose of this Funding Opportunity Announcement (FOA) is to create rodent reporter models for testing in vivo genome editing technologies, and to use these animal models to test genome editing delivery technologies and new genome editors developed under RFA-RM-18-016 and RFA-RM-18-017. The deliverables from the initiative will be a set of animal models (mice and rat), containing one or more reporter genes expressed in all cell types, that will allow facile and quantitative evaluation of genome editing in any cell type of interest. The testing Centers will use these models to validate new delivery systems and genome editing tools developed by other investigators in the Somatic Cell Genome Editing Program. The creation and testing of these rodent models will accelerate the translation of genome editing technologies into treatments for human diseases.

Currently, crime and forensics labs across the country are overwhelmed. This backup can often lead to delays in forensic lab testing and analysis, leading to a ripple effect of delayed prosecution and adjudication throughout the system. While some forensic analysis must be conducted in a laboratory environment, other methods are emerging, like rapid drug testing, that can be performed in the field. Currently, a lack of training and technical assistance related to the development and implementation of these technologies and techniques at the local level exists. This program seeks to fill that void. Under this program, BJA will select an applicant to establish a pilot program to develop a nationwide training model, led by an accredited institution of higher learning, pertaining to available rapid identification technology and scientifically sound field collection and testing methods which can be used when drugs are discovered in the field. The training should support evidence collection and testing technologies and methods that are reliable within State and Local court system.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.

This Funding Opportunity Announcement (FOA) solicits research grant applications which will: 1) advance measurements of intersectional stigma (multiple stigmatized identities) and examine the mechanisms and pathways by which it is a barrier to HIV testing and linkage to prevention; or 2) develop and test interventions to reduce intersectional stigma and improve the uptake of HIV testing and linkage to ongoing HIV prevention among key populations at substantial risk for HIV infection. RFA-MH-19-412 uses the R01 grant mechanism, and RFA-MH-19-410 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or include longitudinal analysis may be appropriate for the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider using the R34 mechanism.

This funding opportunity is for competitive grants to be awarded under the OAA Title IV authority to increase the evidenced based knowledge base of nutrition providers, drive improved health outcomes for program recipients by promoting higher service quality, and increase program efficiency through innovative nutrition service delivery models. Funding will support innovative and promising practices that move the aging network towards evidenced based practices that enhance the quality, effectiveness of nutrition services programs or outcomes within the aging services network. Innovation can include service products that appeal to caregivers (such as web-based ordering systems and carryout food products), increased involvement of volunteers (such as retired chefs), consideration of eating habits and choice (such as variable meal times, salad bars, or more fresh fruits and vegetables), new service models (testing variations and hybrid strategies) and other innovations to better serve a generation of consumers whose needs and preferences are different. Innovative and promising practices may include the testing and publishing of positive outcomes in which nutrition programs provide a meaningful role in support of the health and long-term care of older individuals. Outcomes should focus on methods to improve collaboration with local health care entities, decrease health care costs for a specific population or decrease the incidence of the need for institutionalization among older adults. Through this program, funds may be used to help develop and test additional models or to replicate models that have already been tested in other community-based settings.

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine a methodology for obtaining drug early warning indicators from expanded testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations - including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. In addition, this method was also tested in two trauma units, with promising results. This project will use similar methodology in criminal justice, health care, and other venues, to include opioid treatment admissions, trauma units or emergency departments, and criminal justice programs such as parole or probation, where biological samples are often collected from clients.

CDC, in collaboration with the National AIDS Control Program/Department of AIDS Control, has successfully laid the foundation for quality standards and approaches within India's vast HIV laboratory network through a previous five-year laboratory strengthening funding opportunity announcement (FOA). Many achievements were made during the course of the five-year project period, including accreditation of national and state reference labs. This follow-on FOA is expected to build upon and sustain previous accomplishments through onsite mentoring and in service staff training with an eye to higher quality services and scale up. A plan will be developed to facilitate laboratory quality at the grassroots level for 12,000 + Integrated HIV Testing and Counseling Centers (ICTCs). This shall be done through trainer/mentor creation within the HIV laboratory network to assist peripheral laboratories in implementing minimum quality standards. Given its expanded technical assistance (TA) scope, it is also expected to build the capacity and assure quality in a phased manner for HIV related tests like CD4 enumeration, HIV viral load and STI through strengthening leadership and mentoring capacity within the laboratory network. Now in Phase IV of its HIV/AIDS response, the Government of India (GoI) is keen to address any gaps in Testing coverage.

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine a methodology for obtaining drug early warning indicators from expanded testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations - including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. 

The purpose of this NOFO is to provide funding and technical assistance for PEPFAR countries to establish HIV recent infection surveillance to detect recent infections, monitor trends in the HIV epidemic, identify hot spots associated with recent HIV transmission, and inform programmatic interventions to reach epidemic control. Point-of-care tests for recent infection distinguish between recent (HIV seroconversion in the last 6 months, on average) and non-recent HIV infection and provide results within minutes. These data may be linked to HIV case-based surveillance for ongoing epidemic monitoring and used by programs to provide enhanced counselling for immediate ART initiation, prioritize index testing, and intervene to prevent HIV transmission. This NOFO will require a multi-disciplinary team with expertise in surveillance, laboratory, prevention, HIV testing services, health informatics, data management, data analytics, and supply chain to support the planning, implementation, and impact evaluation of this PEPFAR priority activity.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

PEPFAR South Sudan collaborates closely with the Republic of South Sudan (RSS) Ministry of Health (MOH) and other key partners to implement the HIV/AIDS National Strategic Plan (NSP) and has developed a five year PEPFAR strategy for the RSS. By targeting geographic areas with high HIV prevalence, PEPFAR will assist the RSS to reach the HIV programmatic goal/tipping point of 16,000 net new HIV patients on treatment and an annual reduction of new HIV infections to below 13,000 by 2017. A primary objective to reach this goal requires improved availability and quality of HIV services for families and other high-impact populations using a public health approach. Under this funding opportunity announcement (FOA), PEPFAR South Sudan prioritizes working in collaboration with the MOH to implement the following approaches: 1) expand HIV testing and counseling (HTC) through high-yield testing approaches, 2) improve access to ART services for pregnant and breastfeeding mothers, their partners, and children, 3) strengthen pediatric HIV testing, care and treatment within a family centered approach, and 4) advance the development of a sustainable infrastructure for South Sudan's workforce. This FOA solicits a combination of capacity building and mentorship for the RSS MOH at the national, state and local levels as well as through direct service delivery to complement the MOH, Global Fund and other partner efforts to scale-up HIV prevention, care and treatment programs in South Sudan.

The purpose of this funding opportunity announcement (FOA) is to build laboratory capacity and improve the provision of HIV, TB, and sexually transmitted infections/ opportunistic infections (STI/OI) testing activities and disease monitoring to scale up HIV/AIDS prevention and care and treatment programs. This funding opportunity announcement (FOA) is intended to enhance the four recognized pillars of the Lesotho National Laboratory Strategic Plan (NLSP 2013/4-2018/19) : accessibility, reliability, affordability, and sustainability of laboratory services. The project will support the provision of quality laboratory services as an integral element of the HIV/AIDS prevention and care and treatment programs. The activities include strengthening of referral testing and networking of laboratories, point of care testing (POCT), laboratory quality improvement initiatives, laboratory equipment and supply chain management, and laboratory information and data management system. 

Developers and innovators have many great ideas and products that could improve the U.S. health care system and make life better for patients and care providers. However, effecting actual change is extremely difficult due to the high barriers to entry in the health IT space. Once an innovative new product has been developed, it needs to be tested in real-life care settings. But providers can be hesitant to host this testing for a myriad of reasons-they may have had bad experiences in the past, be anxious about deploying new tools that may disrupt their workflows, or be wary of encountering more problems than the solution solves. Without this testing, it cannot be determined how well the product actually works, making it difficult for the developers to identify the changes that need to be made to the product to make it more effective. Furthermore, without evidence of the uses a product can provide it is that much harder to acquire the venture funding that can fuel further advancement and lead to successful entry in the marketplace. The Market R&D Pilot Challenge is intended to help bridge this gap by bringing together health care organizations ("Hosts") and innovative companies ("Innovators") through pilot funding awards and facilitated matchmaking. The Challenge seeks to award pilot proposals in three different domains: Clinical environments (e.g., hospitals, ambulatory care, surgical centers), public health and community environments (community-based personnel such as public health departments, community health workers, mobile medical trucks, school- and jail-based clinics), and consumer health (e.g., self-insured employers, pharmacies, laboratories). Hosts and Innovators will submit joint pilot proposals, with the winners, as determined by an expert panel, proceeding to implement their pilots.